Huang Xinhui, Lai Yongping, Yao Na, Cui Yongliang, Yu Xiaoling, Cai Zhixiong, Tang Yupeng, Huang Yao, Zeng Jinhua
Department of Invasive Technology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China.
Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian 350025, P.R. China.
Oncol Lett. 2021 May;21(5):347. doi: 10.3892/ol.2021.12608. Epub 2021 Mar 3.
Hepatocellular carcinoma (HCC) is a cancer with a poor prognosis and a low survival rate. Previous studies have found that microRNA-1266 (miR-1266) is associated with tumorigenesis and progression of several types of cancer, such as breast cancer and gastric cancer. The aim of the present study was to investigate the effects of miR-1266 on the clinical prognosis and biological behavior of HCC. For this purpose, reverse transcription-quantitative PCR was used to detect the expression of miR-1266 in HCC tissues and HCC cell lines. In addition, Kaplan-Meier survival analysis and Cox regression analysis were used to evaluate the prognostic value of miR-1266. Cell Counting Kit-8 (CCK-8) and Transwell assays were used to analyze the effect of miR-1266 on the biological behavior of cells. The aforementioned assays demonstrated that the examined HCC tissues had a significant upregulation of miR-1266 expression compared with normal tissues (P<0.001). The overexpression of miR-1266 was significantly associated with Tumor-Node-Metastasis stage (P=0.014). The results of the Kaplan-Meier analysis indicated that the 5-year overall survival rate of patients with high expression of miR-1266 was significantly lower compared with patients with low expression of miR-1266 (P=0.015). Cox regression analysis demonstrated that the expression level of miR-1266 could be used as an independent prognostic factor of HCC. CCK-8 and Transwell assays demonstrated that overexpression of miR-1266 promoted the proliferation, migration and invasion of HCC cells. In summary, the findings of the present study indicated that high expression of miR-1266 was positively associated with poor prognosis of patients with HCC and promoted cell proliferation, migration and invasion of HCC cells. miR-1266 may be used as a biomarker for HCC prognosis.
肝细胞癌(HCC)是一种预后较差、生存率较低的癌症。以往研究发现,微小RNA-1266(miR-1266)与多种癌症(如乳腺癌和胃癌)的肿瘤发生及进展相关。本研究旨在探讨miR-1266对HCC临床预后及生物学行为的影响。为此,采用逆转录定量聚合酶链反应检测HCC组织及HCC细胞系中miR-1266的表达。此外,运用Kaplan-Meier生存分析和Cox回归分析评估miR-1266的预后价值。采用细胞计数试剂盒-8(CCK-8)和Transwell实验分析miR-1266对细胞生物学行为的影响。上述实验表明,与正常组织相比,所检测的HCC组织中miR-1266表达显著上调(P<0.001)。miR-1266的过表达与肿瘤-淋巴结-转移分期显著相关(P=0.014)。Kaplan-Meier分析结果表明,miR-1266高表达患者的5年总生存率显著低于miR-1266低表达患者(P=0.015)。Cox回归分析表明,miR-1266的表达水平可作为HCC的独立预后因素。CCK-8和Transwell实验表明,miR-1266的过表达促进了HCC细胞的增殖、迁移和侵袭。总之,本研究结果表明,miR-1266的高表达与HCC患者的不良预后呈正相关,并促进了HCC细胞的增殖、迁移和侵袭。miR-1266可能用作HCC预后的生物标志物。